Lake Street Capital Markets Analyst, Thomas Flaten, initiated coverage of Ensysce Biosciences, Inc. with a BUY rating and price target of $4 (ENSC - $4). Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms.
None of the information contained in this website constitutes a recommendation, solicitation or offer by Lake Street Capital Markets or its affiliates to buy or sell any securities, options or other financial instruments or provide any investment advice or service. Certain transactions give rise to substantial risk and are not suitable for all investors. Past performance does not guarantee future results.
920 Second Avenue South
Suite 700
Minneapolis, MN 55402
Copyright © 2020 Lake Street Capital Markets
